Brian Park, PharmD

Drug Information Specialist https://www.clinicalpainadvisor.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

Acute Pain

Injectable NSAID Recalled Due to Particulate Matter Found in Vials

Brian Park, PharmD

January 14, 2021

Fresenius Kabi announced the voluntary recall of a single lot of Ketorolac Tromethamine Injection, USP, 30mg/mL, 1 mL fill in a 2 mL amber vial.

Opioid Addiction

FDA Strengthens REMS for Transmucosal Immediate-Release Fentanyl

Brian Park, PharmD

January 5, 2021

While the use of TIRF medications has declined in recent years, data have suggested that prescribing of these drugs to patients who are not opioid tolerant still remains.

Migraine & Headache

NDA Submitted for Novel Intranasal DHE for Migraine

Brian Park, PharmD

November 12, 2020

INP104 uses proprietary technology to deliver a lower dose (1.45mg) of dihydroergotamine mesylate (DHE) to the upper nasal space.

Migraine & Headache

Comparative Efficacy of Erenumab and Topiramate for Chronic Migraine Prevention

Brian Park, PharmD

November 10, 2020

Novartis announced positive results from a phase 4 study comparing treatment with erenumab for episodic and chronic migraine.

Opioid Addiction

DEA Schedules New Intravenous Opioid Oliceridine

Brian Park, PharmD

November 5, 2020

The FDA approved Olinvyk for acute pain severe enough to require an IV opioid analgesic and for whom alternative treatments are inadequate.

Post-Surgical Pain

Bupivacaine Implant Available for Postop Pain After Hernia Surgery

Brian Park, PharmD

November 3, 2020

Bupivacaine implant is now available for acute postsurgical pain relief for up to 24 hours in adults.

Migraine & Headache

Nerivio Device Cleared for Use in Patients With Chronic Migraine

Brian Park, PharmD

October 29, 2020

The FDA has expanded the approval of Nerivio® to include acute treatment of migraine with or without aura in patients aged 18 years and older with chronic migraine.

Migraine & Headache

FDA Rejects Qtrypta NDA for Acute Treatment of Migraine

Brian Park, PharmD

October 27, 2020

Qtrypta delivers zolmitriptan using the Company’s proprietary Adhesive Dermally-Applied Microarray (ADAM) technology that consists of a drug-coated microneedle patch.